CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Insulet delivered solid Q1 2026 results with revenue of $761.7M (+33.9% Y/Y) exceeding guidance and beating consensus by $32M, while adjusted EPS of $1.42 (+39.2%) surpassed expectations by $0.23. Omnipod revenue grew 36.9% to $758.4M, led by 28.3% U.S. growth and 59.4% international expansion, with adjusted operating margin expanding 110 bps to 17.5% despite gross margin pressure. We view the Type 2 diabetes AID progress positively, with encouraging EVOLUTION 2 trial data showing 68% time in range and first participant enrolled in the pivotal EVOLVE study for 2027 510(k) filing. Management raised its 2026 revenue guidance to 21%-23% Y/Y constant currency growth (from 20%-22% Y/Y previously), while maintaining ~100 bps adjusted operating margin expansion and over 25% adjusted EPS growth outlook. We believe the combination of accelerating international momentum, Type 2 diabetes opportunity, and strong cash generation positions Insulet well for continued growth.